CPHRF Stock Chart & Stats
$10.87
-$0.10(-0.92%)
At close: 4:00 PM EST
$10.87
-$0.10(-0.92%)
Day’s Range― - ―
52-Week Range$8.64 - $15.00
Previous CloseN/A
Volume27.53K
Average Volume (3M)13.12K
Market Cap
$292.62M
Enterprise Value$462.58
Total Cash (Recent Filing)$6.41M
Total Debt (Recent Filing)$428.30K
Price to Earnings (P/E)9.4
Beta0.19
Next Earnings
Aug 06, 2026EPS Estimate
0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.22
Shares Outstanding25,391,321
10 Day Avg. Volume17,096
30 Day Avg. Volume13,121
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)2.22
Price to Sales (P/S)5.44
P/FCF Ratio9.25
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$15.63Price Target Upside43.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.63
Revenue Forecast (FY)$37.90M
Bulls Say, Bears Say
Bulls Say
High ProfitabilitySustained very high net margins indicate strong pricing power and/or a high-margin product mix. Over a 2-6 month horizon this underpins cash generation, funds available for reinvestment or licensing, and resilience to moderate revenue swings, supporting long-term earnings quality.
Strong Cash GenerationRobust operating and free cash flow with high conversion of accounting profit into cash supports durable financial flexibility: funds to pay partners, invest in launches, or pursue acquisitions. Consistent FCF reduces refinancing risk and strengthens strategic options.
Conservative Balance SheetVery low leverage and a strengthening equity base provide stability and optionality. This conservatism lowers financial risk, enables funding of licensing deals or product rollouts without heavy debt, and improves tolerance for cyclical revenue or margin variability.
Bears Say
Earnings VolatilityMaterial swings in profitability and reported results suggest earnings are influenced by non-recurring items, product mix shifts, or timing effects. This reduces predictability of long-term cash flows, complicates planning for investors and partners, and raises execution risk.
Limited Internal ScaleA very small headcount implies heavy reliance on external partners and outsourcing for commercialization and operations. Over months this constrains the company's ability to scale organically, increases operational concentration risk, and makes execution dependent on third-party capabilities.
Partner/Portfolio ConcentrationBusiness model depends on a few core products and third-party licensees/distributors. That concentration exposes revenue to partner performance, contract terms, and individual product life-cycles, limiting control over growth and increasing downside if a key partner or brand underperforms.
Cipher Pharmaceuticals News
CPHRF FAQ
What was Cipher Pharmaceuticals’s price range in the past 12 months?
Cipher Pharmaceuticals lowest stock price was $8.63 and its highest was $15.00 in the past 12 months.
What is Cipher Pharmaceuticals’s market cap?
Cipher Pharmaceuticals’s market cap is $292.62M.
When is Cipher Pharmaceuticals’s upcoming earnings report date?
Cipher Pharmaceuticals’s upcoming earnings report date is Aug 06, 2026 which is in 11 days.
How were Cipher Pharmaceuticals’s earnings last quarter?
Cipher Pharmaceuticals released its earnings results on May 07, 2026. The company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.135 by $0.105.
Is Cipher Pharmaceuticals overvalued?
According to Wall Street analysts Cipher Pharmaceuticals’s price is currently Undervalued.
Does Cipher Pharmaceuticals pay dividends?
Cipher Pharmaceuticals does not currently pay dividends.
What is Cipher Pharmaceuticals’s EPS estimate?
Cipher Pharmaceuticals’s EPS estimate is 0.21.
How many shares outstanding does Cipher Pharmaceuticals have?
Cipher Pharmaceuticals has 25,391,321 shares outstanding.
What happened to Cipher Pharmaceuticals’s price movement after its last earnings report?
Cipher Pharmaceuticals reported an EPS of $0.24 in its last earnings report, beating expectations of $0.135. Following the earnings report the stock price went up 9.961%.
Which hedge fund is a major shareholder of Cipher Pharmaceuticals?
Currently, no hedge funds are holding shares in CPHRF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cipher Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-12.52%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.01%
Trailing 12-Months
Company Description
Cipher Pharmaceuticals
Cipher Pharmaceuticals Inc., founded in 2000 and based in Oakville, Canada, operates as a specialized pharmaceutical enterprise. The company markets a diverse portfolio of commercial therapeutic solutions. These include Epuris (CIP-ISOTRETINOIN), formulated for severe acne; Ozenoxacin, targeting impetigo in both adult and pediatric patients; Actikerall, prescribed for palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a topical cream designed to mitigate unwanted facial hair growth in women; BRINAVESS, utilized for restoring sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet medication. Beyond its directly marketed offerings, Cipher's portfolio encompasses various licensed products, such as CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), used in the management of hyperlipidemia, a lipid metabolism disorder; and Conzip/Durela (CIP-Tramadol), indicated for the relief of moderate to moderately severe pain. Looking to the future, Cipher maintains a robust developmental pipeline, which includes Trevyent, a vasodilatory prostacyclin analogue aimed at treating pulmonary arterial hypertension; CF-101, under investigation for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical terbinafine formulation for onychomycosis; and DTR-001, a novel cream for tattoo removal.
CPHRF Company Deck
CPHRF Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth and significant debt reduction, supported by the robust performance of the Natroba business. However, challenges remain in licensing revenue and the Absorica portfolio, along with increased SG&A costs. Overall, the positive aspects slightly outweigh the negative aspects.View all CPHRF earnings summariesCPHRF Stock 12 Month Forecast
Average Price Target
$15.63
▲(43.81% Upside)
Technical Analysis
Knight Therapeutics
―
Medexus Pharmaceuticals Inc
―
Biosyent
―
HLS Therapeutics Inc
―
Cardiol Therapeutics
―
Ownership Overview
43.12% Insiders
0.93% Mutual Funds
2.59% Other Institutional Investors
53.25% Public Companies and
Individual Investors